Welcome

ZGene is dedicated to the discovery and development of novel treatments to satisfy unmet medical needs. ZGene's core business focuses on the treatment of cancer diseases by the delivery of enhanced activators of anti-cancer drugs.

ZGene is developing the ZAS™ platform technology, which efficiently enhances the effect of current anti-cancer drugs and reduces their toxicity. The research portfolio covers the most common cancer types such as breast, pancreatic, bladder, lung and brain cancer.

ZGene is specialized in developing genetically enhanced enzymes, which can activate FDA approved anti-cancer and anti-viral drugs. The activators can be delivered by any delivery system, viral or non-viral. ZGene offers this suicide gene technology as a safety mechanism for companies focused on gene delivery.

Link